What is the most likely diagnosis for a patient with microcytic hypochromic anemia, target cells, elevated serum iron, and normal hemoglobin electrophoresis?

Sideroblastic Anemia

The most likely diagnosis is sideroblastic anemia, specifically X-linked sideroblastic anemia (XLSA) due to ALAS2 defects, which is the most common genetic form of sideroblastic anemia. 1

Diagnostic Reasoning

The clinical presentation of microcytic hypochromic anemia with target cells, elevated serum iron, and normal hemoglobin electrophoresis points strongly toward a disorder of heme synthesis rather than hemoglobinopathy or iron deficiency:

Key Distinguishing Features

• Normal hemoglobin electrophoresis effectively rules out thalassemia and most hemoglobinopathies, which would show abnormal hemoglobin patterns 2, 3

• Elevated iron with microcytic anemia is paradoxical and indicates iron loading with impaired iron utilization—a hallmark of sideroblastic anemia 1, 4

• Target cells can appear in both hemoglobinopathies and sideroblastic anemia, but combined with elevated iron and normal electrophoresis, this strongly suggests sideroblastic anemia 1

Pathophysiology

XLSA results from ALAS2 gene defects causing decreased protoporphyrin synthesis and reduced iron incorporation into heme. This leads to:

• Erythroid mitochondrial iron loading
• Ineffective erythropoiesis
• Increased intestinal iron absorption
• Systemic iron accumulation 1

Essential Next Steps

Obtain a bone marrow aspirate with Perls Prussian blue staining to identify ring sideroblasts—this is the definitive diagnostic test. 4 Ring sideroblasts are pathognomonic for sideroblastic anemia and will be present in XLSA.

Additional Confirmatory Testing

1. Check transferrin saturation (TSAT) and serum ferritin—both will be elevated in XLSA 1

2. Measure red cell distribution width (RDW)—typically elevated, especially in female carriers due to two erythrocyte populations 1

3. Genetic testing for ALAS2 mutations confirms the diagnosis and guides family screening 1

4. Assess for iron overload complications: liver enzymes, liver imaging (MRI or ultrasound), and screen for hepatic fibrosis or hepatocellular carcinoma 1

Important Clinical Pitfalls

Common Diagnostic Errors

• Do not assume iron deficiency anemia based solely on microcytosis—iron-refractory microcytic anemia with elevated iron indices should immediately trigger reassessment 4

• Do not overlook XLSA in females—while X-linked, women can be affected due to skewed X-inactivation, particularly with increasing age 1

• Do not diagnose as myelodysplastic syndrome (MDS) prematurely in elderly patients—ALAS2 defects should be considered in older patients presenting with refractory anemia with ring sideroblasts, especially if microcytic 1

Treatment Considerations

Initiate a trial of pyridoxine (vitamin B6) 50-200 mg daily—this is effective in improving both anemia and iron overload in responsive XLSA patients 1

Critical management points:

• Never give iron supplementation—these patients already have iron overload 4
• Do not label as pyridoxine-refractory until iron stores are normalized—iron overload itself compromises mitochondrial function and heme biosynthesis 1
• Treat iron overload with phlebotomy when possible—hemoglobin typically increases rather than decreases after iron removal 1
• Maintenance pyridoxine dose can be lowered to 10-100 mg daily after response to avoid neurotoxicity 1

Alternative Diagnoses to Consider

If ring sideroblasts are absent on bone marrow examination, consider:

• SLC11A2 (DMT1) defects: microcytic anemia with elevated TSAT but variable ferritin, may have liver iron loading despite normal ferritin 1
• GLRX5 defects: rare autosomal recessive, presents with progressive microcytic anemia, elevated TSAT and ferritin, often with hepatosplenomegaly 1
• Acquired sideroblastic anemia: particularly in older patients, may be secondary to medications, toxins, or early MDS 4